Canadian Cancer Trials Group Bulletins

General


Trial Citations

>IND198 Citation https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-017-0836-3

Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (ONLINE). Breast Cancer Research 19: 54, 2017.


MA31 Citation http://link.springer.com/article/10.1007%2Fs10549-017-4273-x

Ho D, Huang J, Chapman JA, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab) (ONLINE). Breast Cancer Res Treat 1-10, 2017.